Calcium Channel Blockers:
The drugs named calcium channel blockers (CCBs) were initially termed cal cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in seve...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Basel
Birkhäuser Basel
2004
|
| Schriftenreihe: | Milestones in Drug Therapy
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | The drugs named calcium channel blockers (CCBs) were initially termed cal cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2) |
| Beschreibung: | 1 Online-Ressource (XIV, 262 p) |
| ISBN: | 9783034878593 |
| DOI: | 10.1007/978-3-0348-7859-3 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046149324 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9783034878593 |9 978-3-0348-7859-3 | ||
| 024 | 7 | |a 10.1007/978-3-0348-7859-3 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-3-0348-7859-3 | ||
| 035 | |a (OCoLC)1119010985 | ||
| 035 | |a (DE-599)BVBBV046149324 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 615 |2 23 | |
| 084 | |a XI 4400 |0 (DE-625)153006:12905 |2 rvk | ||
| 100 | 1 | |a Godfraind, Théophile |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Calcium Channel Blockers |c by Théophile Godfraind |
| 264 | 1 | |a Basel |b Birkhäuser Basel |c 2004 | |
| 300 | |a 1 Online-Ressource (XIV, 262 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Milestones in Drug Therapy | |
| 520 | |a The drugs named calcium channel blockers (CCBs) were initially termed cal cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2) | ||
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Cardiology | |
| 650 | 0 | 7 | |a Calciumantagonist |0 (DE-588)4069807-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Calciumantagonist |0 (DE-588)4069807-5 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034895996 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783764364359 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034878609 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-0348-7859-3 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031529501 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-3-0348-7859-3 |l UBR01 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180490774642688 |
|---|---|
| any_adam_object | |
| author | Godfraind, Théophile |
| author_facet | Godfraind, Théophile |
| author_role | aut |
| author_sort | Godfraind, Théophile |
| author_variant | t g tg |
| building | Verbundindex |
| bvnumber | BV046149324 |
| classification_rvk | XI 4400 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-3-0348-7859-3 (OCoLC)1119010985 (DE-599)BVBBV046149324 |
| dewey-full | 615 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615 |
| dewey-search | 615 |
| dewey-sort | 3615 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-3-0348-7859-3 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03390nmm a2200505zc 4500</leader><controlfield tag="001">BV046149324</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783034878593</subfield><subfield code="9">978-3-0348-7859-3</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-0348-7859-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-0348-7859-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119010985</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046149324</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4400</subfield><subfield code="0">(DE-625)153006:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Godfraind, Théophile</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Calcium Channel Blockers</subfield><subfield code="c">by Théophile Godfraind</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">Birkhäuser Basel</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIV, 262 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Milestones in Drug Therapy</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The drugs named calcium channel blockers (CCBs) were initially termed cal cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034895996</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783764364359</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034878609</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-0348-7859-3</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031529501</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-0348-7859-3</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046149324 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:36Z |
| institution | BVB |
| isbn | 9783034878593 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031529501 |
| oclc_num | 1119010985 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XIV, 262 p) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Birkhäuser Basel |
| record_format | marc |
| series2 | Milestones in Drug Therapy |
| spelling | Godfraind, Théophile Verfasser aut Calcium Channel Blockers by Théophile Godfraind Basel Birkhäuser Basel 2004 1 Online-Ressource (XIV, 262 p) txt rdacontent c rdamedia cr rdacarrier Milestones in Drug Therapy The drugs named calcium channel blockers (CCBs) were initially termed cal cium antagonists (see Chapter 1). They are also designated as calcium entry blockers (CEBs), calcium blockers, calcium channel antagonists, calcium channel inhibitors (and in French anticalciques). As this is reported in several chapters of this book, their main effect is a blockade of calcium entry into cells through voltage operated calcium channels (VOCCs). Chemically related drugs, such as Bay K 8644, exert the opposite effect by increasing the proba bility of calcium channel opening. One of the subcommittees of the Nomenclature Committee (NC-IUPAR) of the International Union of Pharmacology has been devoted to the classification of calcium channels and the site of action of drugs modifying channel function. The members of this Committee are noted for their significant contribution to the field (Tab. 1). A report has been published in 1992 in Pharmacological Reviews [3]. A list of criteria was approved for the identification of distinct drug binding 2 sites on Ca + channels. It included: (a) the demonstration of a stereoselective binding site supported by drug interaction studies (competition with other drugs, non-competitive interactions with other sites, reversal of inhibitory effects by channel activators); (b) demonstration of the electrophysiologieal effects of the drug and selectivity of action compared to other sites; (c) deter mination of the affinity for the type and subtype of ion channel. These criteria have identified different classes of Ca antagonists (see Chapter 2) Pharmacology/Toxicology Cardiology Toxicology Calciumantagonist (DE-588)4069807-5 gnd rswk-swf Calciumantagonist (DE-588)4069807-5 s 1\p DE-604 Erscheint auch als Druck-Ausgabe 9783034895996 Erscheint auch als Druck-Ausgabe 9783764364359 Erscheint auch als Druck-Ausgabe 9783034878609 https://doi.org/10.1007/978-3-0348-7859-3 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Godfraind, Théophile Calcium Channel Blockers Pharmacology/Toxicology Cardiology Toxicology Calciumantagonist (DE-588)4069807-5 gnd |
| subject_GND | (DE-588)4069807-5 |
| title | Calcium Channel Blockers |
| title_auth | Calcium Channel Blockers |
| title_exact_search | Calcium Channel Blockers |
| title_full | Calcium Channel Blockers by Théophile Godfraind |
| title_fullStr | Calcium Channel Blockers by Théophile Godfraind |
| title_full_unstemmed | Calcium Channel Blockers by Théophile Godfraind |
| title_short | Calcium Channel Blockers |
| title_sort | calcium channel blockers |
| topic | Pharmacology/Toxicology Cardiology Toxicology Calciumantagonist (DE-588)4069807-5 gnd |
| topic_facet | Pharmacology/Toxicology Cardiology Toxicology Calciumantagonist |
| url | https://doi.org/10.1007/978-3-0348-7859-3 |
| work_keys_str_mv | AT godfraindtheophile calciumchannelblockers |